Recent News
Read ArticleDr. Jack Cush reviews the book/movie, "Moneyball" and a suggests moneyball strategy is needed to find next level responses for our patients.
2024 ACR Lupus Nephritis Guidelines: The Controversies
Drs. Maria Dall’Era & Michelle Petri discuss the sticking points in the latest lupus nephritis recommendations.
🗣️ Insightful, honest, and essential for your practice.
📍Full update on RheumNow: https://t.co/KPjyCrMTBr https://t.co/vi7lT7COgQ
Links:
Dr. John Cush @RheumNow ( View Tweet)
2025 ACR Guideline for the Treatment of SLE
The ACR has released its 2025 Systemic Lupus Erythematosus (SLE) treatment guidelines and consensus-based good practice statements, applicable to children and adults with SLE.
https://t.co/2NFwTllLZa https://t.co/Q6smp1ZVH2
Dr. John Cush @RheumNow ( View Tweet)
IMPACT Study - Certolizumab Efficacy in APS Pregnancies
A pilot trial assessed the safety and value of tumour necrosis factor α inhibitor treatment with certolizumab in patients with high-risk pregnancies with antiphospholipid syndrome (APS). Certolizumab (CZP) was shown to https://t.co/776CTvvGfb
Dr. John Cush @RheumNow ( View Tweet)
Shifting the Management Paradigm for SLE and Lupus Nephritis
The paradigm for treating patients with systemic lupus erythematosus (SLE) is rapidly shifting and our patients will surely benefit with improved outcomes.
https://t.co/idxMBTyTwp https://t.co/f5G3cFb3XK
Dr. John Cush @RheumNow ( View Tweet)
QUOTES TO LIVE BY: "it took me a long time be a good listener and be comfortable with silence. Its important to not just throwing facts back to patients who are suffering.
Sometimes pausing is powerful. Its all about establishing relationships " - Dr. Len Calabrese https://t.co/wcKX8nTa2o
Dr. John Cush @RheumNow ( View Tweet)
Hydroxychloroquine: Are Your Patients Taking It?
Dr. Nathalie Costedoat-Chalumeau dives into monitoring HCQ levels and what they tell us about patient adherence.
💡Learn how to spot non-compliance early.
👉 Now live on RheumNow: https://t.co/KPjyCrMTBr
#LupusCare https://t.co/vRASCc9kB0
Links:
Dr. John Cush @RheumNow ( View Tweet)
Time to first musculoskeletal (MSK) response with an IL-23i in PsA: Phase 3 post hoc analyses
View time to first response in key MSK efficacy outcomes and PROs in PsA patients treated with an IL-23i. Sponsored by AbbVie Medical Affairs + Health Impact.
https://t.co/3QTurnvokp https://t.co/VFQEKTQGsk
Dr. John Cush @RheumNow ( View Tweet)
Lupus QD Clinic - All Swells that Ends Well
Workup and management of SLE with periorbital edema, HA and seizures
Featuring Dr. Sheila Reyes, The Philippines
https://t.co/DrelXfe76Z https://t.co/dntYllhjWj
Dr. John Cush @RheumNow ( View Tweet)
5 year cohort study showed that obese T2D (diabetes) pts, semaglutide significantly lowered risk of osteoporosis (HR 0. 61), & gout (HR 0. 63) vs sitagliptin. Semaglutided did not lower the risk of Knee (HR 1. 05) or hip osteoarthritis (HR 0. 88). https://t.co/MqMBKdsXlu https://t.co/VWIGIDhPMO
Dr. John Cush @RheumNow ( View Tweet)
A retrospective VEXAS cohort study of 59 pts receiving 71 targeted Rx - 98%male, mean 71 yrs & 46% had myelodysplastic syndr. Treatments included tocilizumab(19), anakinra (13), azacitidine(13), baricitinib (11), & pred only (10). Best responses w/ azacitidine & tocilizumab https://t.co/jqDmKinPDt
Dr. John Cush @RheumNow ( View Tweet)
Turkish study of 1263 primary care referrals to rheumatology found 35.7% with inflammatory rheumatic Dz (IRD), 17.7% osteoarthritis, and 11.2% regional pain syndromes. Another German study showed low risk of IRD if CRP <5 https://t.co/v5qYb7c7jP https://t.co/iq4NfcC3cH https://t.co/RQan6rQi8a
Links:
Dr. John Cush @RheumNow ( View Tweet)
SLE Treatment Landscape: Abundance or Overload?
Imagine a world where the multiple drugs in Phase 2 and 3 trials actually get approved, and we get access to them? I know you may be thinking that I am overly optimistic, but there are so many drugs in development in lupus that we may have true difficulty choosing what to use.
Read Article
Using publicly available FAERS safety data, drug-induced photosensitivity (DIP) - among 17+ million safety reports, there 20,236 linked to DIP. The most common wereimmunosuppressants, monoclonal Abs, neoplastic agents, including adalimumab, adapalene, secukinumab, fingolimod https://t.co/QWg8FVvrZb
Dr. John Cush @RheumNow ( View Tweet)
50 Year Perspective on Lupus
An observational cohort study was started in Toronto by Dr. Murray Urowitz in 1970. The program was set up as a specialized clinic to provide care for patients with lupus, to study clinical laboratory correlations in the disease, and to better https://t.co/6wuhAAvuCw
Dr. John Cush @RheumNow ( View Tweet)
Genetic Link to CPPD
In a first-of-its-kind genome-wide association study (GWAS) researchers have discovered two genes, RNF144B and ENPP1, that cause calcium pyrophosphate deposition (CPPD) disease in Americans of European and African descent.
https://t.co/YSR6rEYzjG https://t.co/L7JyoxQp3K
Dr. John Cush @RheumNow ( View Tweet)
Contemporary lupus nephritis treatment
The Lupus 2025 congress brought together world SLE thought leaders.
Outcomes in lupus nephritis are akin to the glass half full. Serial monotherapy is out, as the percentage who achieved a complete renal response was very low and some https://t.co/4LVPeDn6r4
Dr. John Cush @RheumNow ( View Tweet)
JAMA -- Full read review "Uveitis in Adults:"
- affects adults 20 to 50 years
- noninfectious anterior uveitis: corticosteroids 1st line Rx
- posterior noninfectious uveitis: DMARDs 1st line Rx; Biologics 2nd line
https://t.co/BJQkPtK2z2 https://t.co/9zAntZK66Q
Links:
Dr. John Cush @RheumNow ( View Tweet)
Lancet viewpoint on early imaging in axial SpA. Over-reliance on BM edema = incr in misDx. Newer tech (high-res sequences, quantitative MRI, radiomics, artificial intelligence) may improve Dx precision. Remember the SI is susceptible to mechanical stress https://t.co/E80GyQGIM0 https://t.co/egIhNP17pQ
Dr. John Cush @RheumNow ( View Tweet)
Early RA or undiff. arthritis (UA) shows initial hi-dose steroids have significantly better earlier outcomes, but lower doses have fewer early side effects. IMPROVED used high dose GC (60 mg/d tapered to 7.5 mg in 7wks). tREACH used lower dose GC (15 mg/d tapered in 10 wks to https://t.co/TkrGPb6EBZ
Dr. John Cush @RheumNow ( View Tweet)
JAMA CME review of Immune Thrombotic Thrombocytopenic Purpura (iTTP) - thrombotic microangiopathy w/ hemolytic anemia (MAHA) & thrombocytopenia. iTTP incidence is 2-6 per million. Caused by Abs to ADAMTS13), w/ low ADAMTS13 activity vWF multimers bind platelets https://t.co/bvCexDPBmq
Dr. John Cush @RheumNow ( View Tweet)
From the blog
Podcasts
Moneyball Rheumatology
Rx Update - Lupus Nephritis
Lupus Unlocked- Pregnancy and SLE
Lupus QD Clinics - lessons from the Clinic - Week 3
Therapeutic Updates
Debunked. Expert perspectives on Sjögren’s Disease myths
Sponsored by Novartis Medical Affairs
How well do you know Sjögren’s disease? Test your knowledge and then hear rheumatologist, Dr Sara McCoy, discuss common myths and realities about managing patients with Sjögren’s disease.
Read Post
Patient Phenotypes Within the Clinical Program of an IL-23 Inhibitor for PsA
Sponsored by AbbVie Medical Affairs + Health Impact
Watch rheumatologist Dr. Alexis Ogdie and rheumatologist and
dermatologist Dr. Saakshi Khattri discuss a new analysis of patient
phenotypes in PsA from clinical trials of an IL-23 inhibitor. In this
conversation, they discuss disease activity differences between
clinical trial populations and real-world patients, efficacy of an IL-23
inhibitor in a bionaïve, moderate PsA phenotype, and the IL-23
inhibitor's potential role in managing patients with PsA.
Read Post
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
Real-world outcomes in patients with RA remaining on first-line TNFi
Daily Gem
PETRI-isms: "The patient is always right (even when they are wrong)." - Dr. Michelle Petri
--